Lilly Obesity Pill to Have Far-Reaching Effect, Doctors Say (1)

Eli Lilly & Co.’s obesity pill prompted enough weight loss in a large clinical trial to be meaningful for patients and have far-reaching implications for the field, doctors said.

The US drugmaker’s tablet orforglipron achieved weight loss of 11.2% in adults with obesity and had side effects in line with the shots available today, said doctors at the European Association for the Study of Diabetes meeting in Vienna. Lilly is presenting full data from the pill’s main obesity trial at the meeting and publishing it in the New England Journal of Medicine.

The tablet doesn’t appear likely to prompt ...